ong-term Continuous Methimazole or Radioiodine Treatment for Hyperthyroidism
Phase 2
- Conditions
- Condition 1: Hyperthyroidism. Condition 2: anti-thyroid drugs.Thyrotoxicosis [hyperthyroidism]
- Registration Number
- IRCT201009224794N1
- Lead Sponsor
- Research Institute for Endocrine Sciences,Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 239
Inclusion Criteria
Age older than 19 years
Biochemically defined overt hyperthyroidism
No history or evidence of cardiovascular diseases
No history or evidence of chronic heart failure
No history or evidence of chronic kidney disease
No history or evidence of cirrhosis
Exclusion Criteria
Evidence of pregnancy
Evidence of breast-feeding
Evidence of altered mental function
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method euro-psychologic condition. Timepoint: at the beginning and end of study. Method of measurement: neuro-psychologic tests.;Development of Goiter. Timepoint: any visit and at the end of study. Method of measurement: physical exam.;Thyroid function assessment. Timepoint: Every 6 months during follow up and at the end of study. Method of measurement: laboratory.;Cardiac function. Timepoint: at the end of study. Method of measurement: echocardiography.
- Secondary Outcome Measures
Name Time Method Serum lipid profiles. Timepoint: at the beginning and end of study (during study if needed). Method of measurement: laboratory.;Bone mineral density. Timepoint: at the end of study. Method of measurement: BMD.;Cost. Timepoint: During follow up and at the end of study. Method of measurement: from actual ambulatory and hospital expenses during follow up.